Droplet Digital PCR - A new view on minimal residual disease quantification in acute lymphoblastic leukaemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35691569/
Real-time quantitative polymerase chain reaction (qPCR) using T-cell receptor/immunoglobulin gene rearrangements has been used as gold standard for minimal residual disease (MRD) monitoring in acute lymphoblastic leukaemia (ALL) for more...
Conclusion: The prospective study demonstrates that ddPCR outperforms qPCR with a significantly better quantitative limit of detection and sensitivity. The number of critical MRD estimates below quantitative limit was reduced by 6- and by 3-fold in the retrospective and prospective cohorts, respectively. Furthermore, the concordance of...
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35666958/
doi: 10.1200/JCO.21.01365. Online ahead of print. 1 Clinica Universidad de Navarra, Cancer Center Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA),...
Conclusion: Evaluation of CTCs in PB outperformed quantification of BM PCs. The detection of ≥ 0.01% CTCs could be a new risk factor in novel staging systems for patients with transplant-eligible MM.
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35666982/
doi: 10.1200/JCO.21.01393. Online ahead of print. 1 SSD Clinical Trial in Oncoematologia e Mieloma Multiplo, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di...
Conclusion: In multiple myeloma, increasing levels of CTC above an optimal cutoff represent an easy-to-assess, robust, and independent high-risk factor. The achievement of MRD negativity is the most important factor that modulates their negative prognostic impact.
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35653225/
In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib-dexamethasone (Isa-Kd) vs...
Conclusion: In conclusion, Isa-Kd provides a consistent benefit vs Kd in elderly patients, with a manageable safety profile, and represents a new treatment option for patients with relapsed MM, independent of age.
Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience
Source : https://journal.waocp.org/article_90115.html
Asian Pacific Journal of Cancer Prevention (APJCP)
Conclusion: Patients with complete remission and negative MRD exhibited significantly higher overall survival when compared to patients having MRD positivity (P value 0.027). Conclusion: MRD is a powerful predictor of outcome in ALL and its positivity at different time points is associated with poor prognostic factors as well as survival...